Impact of antiretroviral drugs in pregnant women and their children in africa: HIV resistance and treatment outcomes

Journal of Infectious Diseases

Volumn 207, Issue SUPPL.2, 2013, Pages

  Paredes, Roger ^a,b   Marconi, Vincent C ^c,d,e   Lockman, Shahin ^f,g,h   Abrams, Elaine J ^i,j   Kuhn, Louise ^i,k  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

ⁱ Department of Medicine   (United States)

^j New York Presbyterian Columbia University Medical Center   (United States)

^k Vagelos College of Physicians and Surgeons   (United States)

more..

Author keywords

antiretroviral therapy; HIV; mother to child transmission; prophylaxis; resistance

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS LOPINAVIR PLUS RITONAVIR PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CHILD HEALTH; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG SAFETY; GENE FREQUENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL WELFARE; NEWBORN CARE; OVERALL SURVIVAL; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VERTICAL TRANSMISSION;

ANTIRETROVIRAL THERAPY; HIV; MOTHER-TO-CHILD TRANSMISSION; PROPHYLAXIS; RESISTANCE;

AFRICA; ANTI-RETROVIRAL AGENTS; CHILD; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PATIENT COMPLIANCE; POVERTY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME;

EID: 84878290980     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit110     Document Type: Article

References (30)

1. Siegfried N, Van derMerwe L, Brocklehurst P, Sint T. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection (Review). Cochrane Database Syst Rev. 2011; (7):CD003510.
2. Arrivé E, Newell M-L, Ekouevi DK, et al. Prevalence of resistance to ne-virapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-21.
3. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8: e1000430.
4. Lockman S, Hughes M, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010; 363:1499-509.
5. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-47.
6. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-20.
7. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global plan towards the elimination of New HIV infections among children by 2015 and keeping their mothers alive. 2011.
8. WHO, UNICEF, UNAIDS. Global HIV/AIDS response. Epidemic update and health sector progress towards Universal Access. Progress Report 2011. 2011.
9. Walter J, Kuhn L, Kankasa C, et al. Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. BMC Infect Dis 2008; 8:172.
10. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-5.
11. Stringer JSA, McConnell MS, Kiarie J, et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevira-pine: a multi-country, prospective cohort study. PLoS Med 2010; 7: e1000233.
12. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J Antimicrob Chemother 2009; 63:170-7.
13. Wind-Rotolo M, Durand C. Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis. 2009; 199: 1301-9.
14. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-72.
15. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA 2011; 108:9202-7.
16. Lockman S, Hughes M, Sawe F, et al. Nevirapine-versus lopinavir/rito-navir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 2012; 9:e1001236.
17. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366:2380-9.
18. Micek MA, Blanco AJ, Carlsson J, et al. Effects of short-course zidovu-dine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine. J Infect Dis 2012; 205:1811-5.
19. Mcintyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 2009; 6:e1000172.
20. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricita-bine for reduction of viral resistance to non-nucleoside reverse tran-scriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-705.
21. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose ne-virapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr. 2009; 51:522-9.
22. World Health Organization. Technical update on treatment optimization. Use of efavirenz during pregnancy: a public health perspective. J Infect Dis. 1998; 177:557-64.
23. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177:557-64.
24. Aizire J, McConnell MS, Mudiope P, et al. Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine. J Acquir Immune Defic Syndr (1999) 2012; 60:483-8.
25. Hauser A, Sewangi J, Mbezi P, et al. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission. PloS One 2012; 7:e32055.
26. Paredes R, Cheng I, Kuritzkes DR, Tuomala RE, Group W, ITS (WITS). Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS (London, England) 2010; 24:45-53.
27. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS (London, England) 2005; 19:63-7.
28. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378:282-4.
29. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS (London, England) 2012; 26:2039-52.
30. Ciaranello AL, Perez F, Engelsmann B, et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis 2013; 56:430-46.